“the ITP was the first study that really put rapamycin on the map in 2009 that was the study that's fortuitously demonstrated that even when rapamycin was given very very late in life it was given to 60 month old mice it still afforded them a 15% lifespan extension”
Main Takeaways:
- Rapamycin was shown to extend lifespan by 15% even when administered late in life to mice.
- The study was conducted under the Interventions Testing Program (ITP), a rigorous NIH-funded program.
- This finding highlights the potential of rapamycin as a longevity-enhancing substance.
Notes: Discussing the impact of rapamycin in longevity studies
Tone: Informative
Relevance: 5/5
“the two drugs i get asked about more than all other drugs combined namely metformin and rapamycin or the category of analogues to rapamycin known as rapalogs”
Main Takeaways:
- Metformin and rapamycin are frequently discussed in the context of longevity and health.
- Rapalogs are analogues of rapamycin, indicating a broader category of related substances.
Notes: Setting the stage for a detailed discussion on these substances
Tone: enthusiastic
Relevance: 5/5
“their potential for reducing the risk of saros cov2 infection or other infections and of course covet 19 morbidity”
Main Takeaways:
- Metformin and rapamycin may have potential roles in reducing the risk of COVID-19 and other infections.
- These substances could influence disease outcomes by modulating the immune response.
Notes: Speculation on the role of metformin and rapamycin in infection control
Tone: cautious
Relevance: 4/5
“Novartis had a rapamycin analog and there was a lot of data that mTOR inhibitors have beneficial effects on aging and lifespan.”
Main Takeaways:
- Rapamycin analogs are linked to potential anti-aging benefits.
- mTOR inhibitors are studied for their effects on lifespan extension.
Notes: Discussion about the choice of substance for a clinical trial.
Tone: Informative
Relevance: 4/5
“older mice given rapamycin that vaccination response was improved”
Main Takeaways:
- Rapamycin improved vaccination responses in older mice.
- Suggests potential benefits of rapamycin in enhancing immune function in the elderly.
Notes: Discussing the potential of rapamycin in medicine
Tone: Optimistic
Relevance: 4/5
“we used very unusual dosing regimens of this rapamycin analog that we either dosed at a very low dose once daily or once weekly”
Main Takeaways:
- Experiment involved unusual dosing regimens of a rapamycin analog.
- Dosing was either low dose daily or weekly to partially inhibit mTOR.
Notes: Explaining the methodology of the study
Tone: Informative
Relevance: 5/5
“when they added rapamycin to metformin to rapamycin you could say if you think metformin has no effect that was that was cohort seven that was a nine-month intervention or they were they treated the mice at nine months with metformin and rappa together”
Main Takeaways:
- A study combined metformin and rapamycin in a treatment for mice.
- The intervention lasted nine months and started when the mice were nine months old.
- This combination treatment is part of a broader study to assess effects on longevity.
Notes: Explaining the setup of a specific cohort within a study.
Tone: Neutral
Relevance: 4/5
“Joan, I started taking metformin in 2010, that's when I sort of became pretty convinced about the data. I started taking rapamycin in 2018, it's been about two years.”
Main Takeaways:
- The speaker started using metformin in 2010 due to convincing data.
- Began using rapamycin in 2018, indicating a belief in its benefits after eight years of using metformin.
- The combination of these substances is part of a personal regimen, not necessarily a recommended practice for all.
Notes: Personal anecdote about substance use.
Tone: Neutral
Relevance: 4/5
“The reason I chose metformin, it's not because it was the best drug, I think rapamycin should be a better drug but it's because we didn't want to kill anyone on the road to success.”
Main Takeaways:
- Metformin was chosen for safety reasons over potentially more effective alternatives like rapamycin.
- The speaker acknowledges a preference for rapamycin based on its potential but prioritizes safety in drug selection.
- This statement reflects a cautious approach to drug recommendation and usage.
Notes: Discussion on drug selection criteria.
Tone: Cautious
Relevance: 4/5
“never getting one again until i started rapamycin you know 12 14 years later that's been the only thing i've noticed”
Main Takeaways:
- Speaker did not experience mouth ulcers again until starting rapamycin years later.
- Rapamycin is implied to have a negative side effect related to oral health.
Notes: Discussing personal experience with rapamycin
Tone: Observational
Relevance: 4/5
“one other little thing i've noticed which is really odd is when i'm on it, it's not surprising my fingernails grow slower”
Main Takeaways:
- Rapamycin appears to slow down fingernail growth according to the speaker's observation.
- This effect is noted as odd but not surprising by the speaker.
Notes: Personal observation shared about the effects of rapamycin
Tone: Curious
Relevance: 3/5
“certainly with respect to the podcasts around rapamycin and metformin”
Main Takeaways:
- Rapamycin and metformin are substances discussed in relation to longevity.
- These substances are part of studies conducted by the Interventions Testing Programs (ITPs).
- The ITPs are considered the gold standard for testing longevity molecules in mice.
Notes: Discussion about the ITPs and their significance in longevity research.
Tone: Informative
Relevance: 4/5
“rapamycin is one of the candidate drugs who brought that to the committee dave sharp dave sharp was a colleague of randy strong's at texas he's an expert on tor the target of rapamycin”
Main Takeaways:
- Rapamycin was introduced as a candidate drug by Dave Sharp.
- Dave Sharp is an expert on TOR (target of rapamycin).
- Rapamycin's potential for longevity was being considered.
Notes: Discussion about the introduction of rapamycin in longevity studies.
Tone: Informative
Relevance: 4/5
“rapamycin is that drug and it's actually safe enough that you can use it in certain high-risk situations in people.”
Main Takeaways:
- Rapamycin is considered safe for use in certain high-risk medical situations.
- It inhibits an enzyme linked to longevity in invertebrate studies.
Notes: Highlighting the safety and application of rapamycin in specific scenarios.
Tone: Reassuring
Relevance: 4/5
“randy strong noticed first of all that when you gave it to mice in the usual form 90 95 percent of it was eaten up in the stomach so randy and dave and their collaborators then spent a year trying to successfully trying to reformulate the rapamycin by coating it in a kind of a shell that would get it through the stomach into the small intestine where it would be absorbed”
Main Takeaways:
- Rapamycin was initially not effective orally as it was mostly destroyed in the stomach.
- A reformulation was developed to protect the drug through the stomach and release it in the small intestine.
Notes: Discussion on the challenges and solutions in formulating rapamycin for effective oral use.
Tone: Technical
Relevance: 5/5
“the first drug that gave a very strong signal in both males and females and it's still the only drug that we've tested so far which gives a very strong signal in females”
Main Takeaways:
- Rapamycin showed significant effects on longevity in both male and female mice.
- It remains the most effective drug tested for increasing longevity in female mice.
Notes: Emphasizing the unique effectiveness of rapamycin across genders in mice.
Tone: Positive
Relevance: 5/5
“when you give the same dose of rapamycin in chow, the blood levels in the females are three times higher than the males”
Main Takeaways:
- Rapamycin dosage results in different blood levels between genders.
- Females exhibit higher blood levels of rapamycin compared to males when given the same dosage.
Notes: Discussion on the effects of rapamycin in an experimental setting
Tone: Neutral
Relevance: 4/5
“so that means of the drugs that we've tested for late start rapamycin works perfectly, acarbose works about half as well as an early start and 17 alpha estradiol seems to work just as well in late middle age.”
Main Takeaways:
- Rapamycin is effective even when started late in life.
- Acarbose has reduced efficacy when started late compared to an early start.
- 17 alpha estradiol maintains effectiveness even when started in late middle age.
Notes: Discussing the effectiveness of substances in aging research.
Tone: Informative
Relevance: 5/5
“what we've learned about rapamycin since that time is it inhibits two complexes of TOR complex one and complex two.”
Main Takeaways:
- Rapamycin inhibits both TOR complex one and two.
- The longevity benefits are primarily attributed to the inhibition of TOR complex one.
Notes: Discussion on the mechanisms of rapamycin and its effects.
Tone: Informative
Relevance: 5/5
“the basic idea that knocking down TOR complex one might be a good thing and that knocking down TOR complex two might be a bad thing.”
Main Takeaways:
- Inhibition of TOR complex one is potentially beneficial.
- Inhibition of TOR complex two might have detrimental effects.
Notes: Summarizing the effects of TOR complex inhibition.
Tone: Cautious
Relevance: 5/5
“randy strong and marty javers and their colleagues at the university of texas did a really useful study they gave rapamycin for a short period of time to male and female mice and then took blood samples every i don't know every hour every two hours or something and the rapamycin blood content in the female mice was two or three times higher than it was in the male mice.”
Main Takeaways:
- Rapamycin was administered to both male and female mice in a study.
- Blood samples were taken periodically to measure rapamycin levels.
- Female mice showed 2-3 times higher rapamycin levels in their blood compared to male mice.
Notes: Discussing gender differences in drug response
Tone: Informative
Relevance: 5/5
“the study that was most informative for rapamycin was to take fresh virgin mice and give them the drug at a defined date at a defined amount and then quickly measure the blood levels after that.”
Main Takeaways:
- A specific study on rapamycin involved administering the drug to fresh virgin mice.
- Blood levels of rapamycin were measured immediately after administration.
Notes: Describing methodology for measuring drug efficacy
Tone: Detailed
Relevance: 4/5
“I went to circus I gave my talk on rapamycin which is what they wanted to hear.”
Main Takeaways:
- Rapamycin was the focus of the talk given at a circus event.
- The audience had a specific interest in hearing about rapamycin.
Notes: Part of a larger discussion on substances studied for longevity.
Tone: Neutral
Relevance: 3/5
“we have two drugs rapamycin and one we didn't mention the amino acid glycine which have equally strong effects in males and females.”
Main Takeaways:
- Rapamycin and glycine have been identified as drugs that effectively extend lifespan in both males and females.
- Glycine's effect, although significant, is described as tiny and thus not a focus of current research.
Notes: Discussion on the sex-specific effectiveness of longevity drugs
Tone: neutral
Relevance: 5/5
“we gave them a lot of my some rapamycin and then instead of letting them die we euthanized them at 22 months of age when most of them were still alive and fairly healthy and then with the aid of a pathologist j irby wilkinson irby looked at dozens of different organs and sue brooks also looked at their tendons so their tendons were youthful their kidneys were youthful they did not have changes in the heart they did not have changes in the endometrium they did not have changes in the liver they did not have changes in the adrenal that were characteristic of 22-month old control mice.”
Main Takeaways:
- Rapamycin was administered to mice, leading to healthier aging indicators across various organs.
- The study involved detailed post-mortem examinations to assess the effects of rapamycin on aging.
- Rapamycin appeared to slow down age-related degenerative changes in mice.
Notes: Discussion on the effects of rapamycin in an experimental setting on mice.
Tone: informative
Relevance: 5/5
“from the mice we've in the rapamycin studies we look we've learned how suppressing this gene called mtor can have multiple health benefits”
Main Takeaways:
- Studies on mice using rapamycin have shown that suppressing the mTOR gene can lead to multiple health benefits.
- The mTOR pathway is a key regulator of cell growth and metabolism.
Notes: Discussion on genetic research findings from animal studies
Tone: Scientific
Relevance: 4/5
“the itp very consistently even you know whether you talk about its home run drugs like rapamycin and other drugs like recently 17 alpha estradiol, they disproportionately favor the male mice over the female mice”
Main Takeaways:
- Discussion on the Intervention Testing Program (ITP) and its findings on gender differences in drug efficacy.
- Mentions specific drugs like rapamycin and 17 alpha estradiol showing different effects based on sex in mice.
- Highlights the need for considering sex differences in therapeutic approaches.
Notes: Discussion on drug testing and sex differences in mice
Tone: Analytical
Relevance: 5/5
“we don't know how long one as a human needs to fast to achieve a significant inhibition of rapamycin to extract the benefits that we think are there”
Main Takeaways:
- The optimal duration of fasting required to inhibit rapamycin and derive associated benefits is not well understood.
- Rapamycin inhibition is considered beneficial in the context of aging and longevity.
Notes: Discussion on biomarkers and aging
Tone: Inquisitive
Relevance: 4/5
“certainly if we go by the mouse data it would have to be rapamycin if we go by the human data it would have to be metformin.”
Main Takeaways:
- Rapamycin shows promising results in mouse studies for longevity.
- Metformin has shown positive effects in human studies related to aging.
Notes: Comparison of substances based on animal and human research data.
Tone: Analytical
Relevance: 5/5
“how would you dose rapamycin in a longevity trial just as a thought experiment given two pieces of evidence that seem to be at dialectical odds with each other.”
Main Takeaways:
- Discussion on dosing rapamycin in longevity trials.
- Challenges highlighted due to conflicting evidence on its effects.
Notes: Theoretical discussion on clinical trial design for rapamycin.
Tone: inquisitive
Relevance: 4/5
“we see that short-term treatment with rapamycin in mice makes an old heart function functionally to some extent more like a young heart”
Main Takeaways:
- Rapamycin treatment in mice has shown to rejuvenate heart function to some extent.
- The treatment does not fully reverse aging but improves certain functional aspects of the heart.
- The effects are observed in the short term.
Tone: cautious
Relevance: 4/5
“with rapamycin you know the data are pretty clear that you can start rapamycin certainly well into middle age and maybe even a very old age and get most of the benefit.”
Main Takeaways:
- Rapamycin shows effectiveness in extending lifespan when started in middle or old age.
- Suggests a different mechanism of action compared to caloric restriction.
- Indicates potential for late-life interventions to promote longevity.
Notes: Discussion on the effectiveness of rapamycin as a late-life intervention.
Tone: Positive
Relevance: 5/5
“he nominated rapamycin it got selected it went into the cohort and they typically test five or six interventions or drugs each year so they have a huge number of animals at each of these three sites that are destined for these interventions to be tested in and rapamycin was one of them.”
Main Takeaways:
- Rapamycin was selected for testing in a cohort that evaluates multiple interventions annually.
- The testing involves a large number of animals across three different sites.
Notes: Discussion on the selection and testing process of interventions in research.
Tone: Neutral
Relevance: 4/5
“once they finally developed this in what they call e-wrap encapsulated rapamycin it it's basically designed so that it won't break down in the gastric ph once they developed that they were now 18 months into this lifespan experiment”
Main Takeaways:
- E-wrap encapsulated rapamycin was developed to prevent breakdown in gastric pH.
- The development took 18 months into the lifespan experiment.
Notes: Discussion on the development of a stable form of rapamycin for experimental purposes.
Tone: Neutral
Relevance: 4/5
“same thing seems to be true in people so you know there are people who are getting their rapamycin from uh from like the rap immune which is the brand name generic or the brand name sarah limus that likes comments comes in these triangle-shaped pills they're also people who are getting it from compounding pharmacies and i've heard of several cases now where the bioavailability is much lower in the the compounded rapamycin in a capsule”
Main Takeaways:
- Rapamycin's stability issues are similar in humans as in mice.
- Bioavailability issues have been noted with compounded forms of rapamycin compared to brand name forms.
Notes: Discussion on the bioavailability of rapamycin in different forms.
Tone: Neutral
Relevance: 4/5
“what the mice are eating and when they last ate has if anything as as big maybe bigger effect on mtor signaling than rapamycin”
Main Takeaways:
- Diet has a significant impact on mTOR signaling, potentially more so than the drug rapamycin.
- The timing and content of meals can influence cellular signaling pathways.
- This highlights the complexity of studying nutrient-signaling interactions.
Notes: Discussion on the effects of diet versus pharmaceutical intervention on cellular pathways in mice.
Tone: Analytical
Relevance: 4/5
“we've learned a ton from these nutritional studies in laboratory animals about the biological mechanisms we've learned a lot about which proteins are and and pathways are important and that has led us to things like rapamycin”
Main Takeaways:
- Nutritional studies in lab animals have helped identify key proteins and pathways that impact longevity.
- This research has contributed to the development of interventions like rapamycin.
Notes: Discussion on the impact of nutritional research
Tone: Educational
Relevance: 4/5
“I got very interested in trying to understand what the mechanisms are for how Rapamycin was affecting the biological aging process.”
Main Takeaways:
- Rapamycin has been studied across various species for its effects on aging.
- It consistently shows positive results in preclinical studies.
- Rapamycin impacts both longevity and health span in complex animals.
Notes: Introduction to the topic of Rapamycin and its study across species.
Tone: Enthusiastic
Relevance: 5/5
“I've worked on Rapamycin my entire scientific career going back to my PhD.”
Main Takeaways:
- David has extensive experience researching Rapamycin.
- His work includes understanding the biochemical mechanisms of mTOR, which Rapamycin affects.
Notes: David provides a background on his long-term research focus on Rapamycin.
Tone: Proud
Relevance: 5/5
“I immediately went and looked up everything I could learn about mtor and found out there's this drug rapy that's an inhibitor of mtor and then we found that we could also increase lifespan with rapy and at this point we were working in yeast but then it became clear to me because of the work of others that this pathway and this drug appeared to affect the biological aging process not only in yeast but also across the animal kingdom.”
Main Takeaways:
- Rapamycin is an inhibitor of the mTOR pathway.
- Research initially in yeast showed that rapamycin could increase lifespan.
- Further studies indicated that rapamycin affects the biological aging process across various species.
Notes: Speaker discussing initial research findings on rapamycin.
Tone: enthusiastic
Relevance: 5/5
“I think through all of that the one thing that that has kind of kept me excited about Ramy as a potential longevity therapeutic is that it always works and I would say without question it is the most robust and reproducible drug at least from pre-clinical studies that we know about today for impacting not only longevity but to the extent that we can measure various metrics of Health span.”
Main Takeaways:
- Rapamycin consistently shows positive results in pre-clinical studies for longevity and health span.
- It is considered robust and reproducible in its effects on aging.
Notes: Speaker emphasizing the consistent effectiveness of rapamycin in research.
Tone: enthusiastic
Relevance: 5/5
“We are actually carrying out a Veterinary clinical trial of ramyon in pet dogs right now we've got some preliminary data but it's too early to be able to say you know with any level of confidence that Romy is going to positively impact the aging process in dogs but I think we've already learned a lot about safety and maybe some hints about efficacy.”
Main Takeaways:
- A veterinary clinical trial of rapamycin in pet dogs is currently underway.
- Preliminary data is available but conclusive results on its efficacy in aging are not yet determined.
- Initial findings suggest information on safety and potential efficacy.
Notes: Discussion of ongoing research involving rapamycin in dogs.
Tone: cautious
Relevance: 4/5
“the discovery of rapamycin is the place to begin this because you know there's a very unique phenomenon here which is the drug was discovered before the Target and the target is named after the drug in response to that.”
Main Takeaways:
- Rapamycin was discovered before its biological target was identified.
- The target of rapamycin was named after the drug itself.
Notes: Discussion on the unique discovery process of rapamycin.
Tone: Informative
Relevance: 4/5
“Rapamycin and other mTOR inhibitors for other uses because it was developed clinically as an organ transplant immunosuppressant and that's how it was first approved.”
Main Takeaways:
- Rapamycin was initially developed and approved as an immunosuppressant for organ transplants.
- The clinical development path of rapamycin may have negatively impacted its testing for other potential uses.
Notes: Discussion on the clinical development and potential broader applications of rapamycin.
Tone: Cautious
Relevance: 4/5
“the first paper that seren seal put out there describing the chemical composition of rapamycin was about 1971 1972 the FDA approval for Rapamycin in humans was 1999”
Main Takeaways:
- Rapamycin was first described in a paper around 1971-1972.
- FDA approved Rapamycin for human use in 1999.
Notes: Discussing the timeline of Rapamycin development and approval.
Tone: Informative
Relevance: 4/5
“we were giving Rapamycin out constantly and to your point Matt it was a drug that was typically given 2 to 3 milligrams a day every single day but with three other drugs right you were also getting prednisone, cellep, MMF you were getting very very toxic drugs because you needed to completely shut down the cellular immune system of a patient who had just received a foreign organ”
Main Takeaways:
- Rapamycin was administered daily at 2 to 3 milligrams along with other drugs like prednisone, cellep, and MMF.
- These drugs were used in combination to suppress the immune system in transplant patients.
Notes: Describing the clinical use of Rapamycin in transplant patients.
Tone: Clinical
Relevance: 5/5
“once we started making that connection of rapamycin into nutrients right which which many groups did uh if you actually look at the history of it and and it was already appreciated for many many decades before that things like caloric restriction had an impact on lifespan”
Main Takeaways:
- Research groups have linked rapamycin with nutrient sensing pathways.
- Historically, caloric restriction has been known to impact lifespan.
Notes: Discussing the connection between rapamycin and nutrient sensing in relation to lifespan.
Tone: Exploratory
Relevance: 4/5
“with rapamycin it's not only the drug but we also have genetic inhibition of mtor in each of those model systems that recapitulates the longevity and health span benefits”
Main Takeaways:
- Rapamycin affects longevity not only as a drug but also through genetic pathways.
- Genetic inhibition of mTOR in model systems shows similar longevity and health span benefits.
- This suggests a strong link between mTOR pathways and longevity.
Notes: Speaker is adding context to another expert's statement on rapamycin.
Tone: Informative
Relevance: 5/5
“there was just recently the first study that I know of that tested a uh ATP competitive mtor inhibitor in mice and it's intriguing I would say early data but we really have no clue as far as I can tell how other classes of mtor Inhibitors would perform relative to rap ayon”
Main Takeaways:
- Recent study tested an ATP-competitive mTOR inhibitor in mice.
- Results are preliminary and it's unclear how this class compares to others like rapamycin.
- Highlights the need for more comparative studies among mTOR inhibitors.
Notes: Discussion on the need for more research on mTOR inhibitors.
Tone: Cautious
Relevance: 4/5
“the catalic Inhibitors basically annihilate the activity of mtor 1 and Mt 2 if used at the right dose rapy partially inhibits mtor 1 and over time can also partially inhibit mtor 2”
Main Takeaways:
- Catalytic inhibitors can completely inhibit the activity of both mTOR 1 and mTOR 2 at the correct dosage.
- Rapamycin partially inhibits mTOR 1 and, with prolonged use, can also inhibit mTOR 2.
Tone: Informative
Relevance: 5/5
“if I use rap for a long period of time I inhibit akt and I also break apart mtor 2”
Main Takeaways:
- Long-term use of rapamycin can inhibit AKT and disrupt mTOR 2.
Notes: Discussion on the effects of prolonged rapamycin use.
Tone: Cautious
Relevance: 5/5
“the assumption that the reason rapy is extending lifespan and affecting healthspan metrics is purely because of the M torque one inhibition and I would say that piece we don't completely know”
Main Takeaways:
- Rapamycin is assumed to extend lifespan and improve healthspan metrics primarily through mTORC1 inhibition.
- The complete mechanisms by which rapamycin affects aging are still not fully understood.
Notes: Discussion on the effects of rapamycin on aging
Tone: Cautious
Relevance: 4/5
“the best evidence for the idea that the benefits of Ramy and come from mtor 1 inhibition is the genetic data which we've sort of alluded to in yeast and worms and flies and mice where you can mutate proteins or genes that code for proteins in mtor complex one and see lifespan and health span benefits”
Main Takeaways:
- Genetic studies in yeast, worms, flies, and mice suggest that mutating genes associated with mTORC1 can extend lifespan and improve healthspan.
- These findings support the hypothesis that mTORC1 inhibition is a key mechanism behind the benefits of rapamycin.
Notes: Discussion on genetic studies supporting mTORC1's role in aging
Tone: Neutral
Relevance: 5/5
“I'm not convinced at this point that the idea that all of the benefits are due to M torque 1 inhibition and all of the side effects are due to mtor 2 inhibition”
Main Takeaways:
- The speaker expresses skepticism about the model that separates the benefits and side effects of rapamycin into mTORC1 and mTORC2 inhibition respectively.
- This indicates a need for further research to accurately understand rapamycin's mechanisms.
Notes: Expressing doubt about the current understanding of rapamycin's effects
Tone: Skeptical
Relevance: 4/5
“you need mtor activation to build new muscle um and so the idea was that rapamycin treatment inhibiting mtor turning down mtor should lead to faster muscle loss that was the prediction that was made so that rapamycin should induce sarcopenia if you were to treat animals with rapamycin as they were getting older that would that was the prediction that was made the reality turns out to be the opposite”
Main Takeaways:
- mTOR activation is necessary for muscle building.
- Rapamycin, which inhibits mTOR, was predicted to accelerate muscle loss and induce sarcopenia.
- Contrary to predictions, rapamycin treatment in animal studies has shown to preserve muscle mass in aging.
Notes: Discussion on the effects of rapamycin on muscle mass and mTOR inhibition
Tone: Surprised
Relevance: 5/5
“I think this brain penetration question again as David I think correctly noted there's disagreements out there about how effectively does Romy cross the blood brain barrier how how much rapamycin do you need to get inhibition of M torque 1 in the brain what I can tell you from our own studies is certainly at higher Doses and I think this matches what what you've seen David is that we see potent inhibition of mtor complex one in the brain after repeated dosing at higher doses where we're using IP injection we haven't really compared this to lower doses where the rapamycin is in the food.”
Main Takeaways:
- There is debate about how effectively rapamycin crosses the blood-brain barrier.
- Higher doses of rapamycin have shown potent inhibition of mTOR complex 1 in the brain in studies.
- The effect of lower doses of rapamycin, especially when administered in food, is less clear.
Notes: Discussion on the challenges of drug delivery to the brain and the effectiveness of rapamycin in inhibiting mTOR in brain tissues.
Tone: Cautious
Relevance: 4/5
“you could treat with Rapa for I think six weeks in that study um and rejuvenate the immune function of a mouse and to me the one experiment in there that is most most compelling is they they have a set of mice I think they were 24 months of age when they started this experiment and then they had young mice and the mice got um either a flu vaccine or no vaccine and then they waited and then they gave them what would be a lethal dose of influenza if they hadn't been vaccinated and then in the Aged mice they either got rap a in for six weeks or they didn't and so if you're a young Mouse and you don't get a vaccine and you get this dose of influenza there's 100% mortality within I think it was 8 days days that makes sense right no vaccine you're not protected against the influenza if you're a young mouse that got the vaccine 100% protection so that again makes sense it's a control if you're an old mouse No rrap a you get a vaccine only 30% of the mice actually were protected so this is showing…”
Main Takeaways:
- Rapamycin treatment for six weeks rejuvenated immune function in aged mice.
- Aged mice treated with rapamycin showed a 100% survival rate against a lethal dose of influenza post-vaccination.
- This study suggests potential for immune rejuvenation treatments in aged populations.
Notes: Discussing a mouse study on immune rejuvenation
Tone: Enthusiastic
Relevance: 5/5
“6 weeks of Romy is enough to knock down chronic sterile inflammation to the point where you have a resetting of immune function which then allows the immune system to appropriately respond in a way that functionally is like a young immune system to a vaccine”
Main Takeaways:
- Short-term treatment with rapamycin can reduce chronic inflammation and reset immune function.
- This treatment makes the immune system of older individuals respond similarly to that of younger individuals.
- Suggests potential for improving vaccine efficacy and overall immune response in older adults.
Notes: Discussing the effects of rapamycin on immune function and inflammation in the context of aging.
Tone: Optimistic
Relevance: 5/5
“whether wrap a mice in toothpaste or wrap a mice in mouthwash or something like that specifically delivered to the oral Cav it is that sufficient to get some of the benefits that we've shown in mice from systemic Rapa and treatment on periodon disease gingival inflammation bone growth around the teeth”
Main Takeaways:
- Exploring localized delivery of rapamycin in oral care products like toothpaste or mouthwash.
- Potential benefits include treatment of periodontal disease, gingival inflammation, and promoting bone growth around teeth.
- This approach aims to leverage systemic benefits of rapamycin specifically for oral health.
Notes: Discussion on experimental approaches in oral health
Tone: Inquisitive
Relevance: 4/5
“depression and anxiety and there's a whole growing body of literature on the role of mtor and inhibition of mtor in various types of neurocognitive behavioral um uh aspects and so it makes me wonder if that actually might be real that that to some extent in some people Romy could actually have some what in this case appear to be beneficial effects on things like depression and anxiety”
Main Takeaways:
- Discussion on the potential beneficial effects of mTOR inhibition on depression and anxiety.
- Suggests that rapamycin might have positive effects on mental health for some individuals.
- Highlights the need for further research into the neurocognitive and behavioral impacts of mTOR inhibitors.
Notes: Exploration of mTOR's role in mental health
Tone: Speculative
Relevance: 4/5
“First of all, no difference in frequency of infection that was significant, so there's no reason to believe based on our data that rapamycin impacted the likelihood that somebody would get a positive COVID-19 result.”
Main Takeaways:
- Rapamycin did not significantly affect the likelihood of contracting COVID-19.
- The study was based on self-reported data without laboratory confirmation.
- No significant difference in infection rates between rapamycin users and non-users.
Notes: Discussing the impact of rapamycin on COVID-19 infection rates.
Tone: Neutral
Relevance: 4/5
“Big difference, at least statistically significant, between people who took rapamycin throughout and all of the other groups where people who took rapamycin throughout had lower severity of infection and statistically significantly less likelihood of reporting symptoms associated with long COVID.”
Main Takeaways:
- Continuous use of rapamycin during COVID-19 infection may reduce severity and long COVID symptoms.
- Statistically significant findings suggest a potential benefit of rapamycin in managing COVID-19.
- Further research is suggested to explore rapamycin's effects on COVID-19.
Notes: Analysis of different usage patterns of rapamycin among COVID-19 patients.
Tone: Cautious
Relevance: 5/5
“I think the real answer is to why mtor and thus Rapa are special is that mtor does a lot of stuff and to impact the aging process you have to do a lot of stuff”
Main Takeaways:
- mTOR's extensive role in cellular processes makes it a key target in aging research.
- Rapamycin (Rapa) is highlighted as significant due to its interaction with mTOR.
- Addressing aging effectively requires influencing multiple cellular mechanisms.
Notes: Explaining the significance of mTOR and Rapamycin in aging
Tone: Informative
Relevance: 5/5
“we can actually design a clinical trial and this is a real clinical trial double blind randomized Placebo controlled Veterinary clinical trial to answer the question does rap ayon slow aging increase lifespan improve multiple healthspan metrics in a reasonable time frame.”
Main Takeaways:
- The trial is designed to rigorously test the effects of a substance on aging and metabolic health.
- It is a double-blind, randomized, placebo-controlled trial, ensuring the reliability of the results.
- The focus is on both lifespan and various healthspan metrics.
Notes: Explaining the structure and purpose of the clinical trial involving dogs.
Tone: Scientific
Relevance: 5/5
“I'm not sure that lifespan so even though we're powered for lifespan that's our primary Endo I'm honestly not sure that's the most important end point for evaluating potential efficacy of rapy in in dogs or people right I mean I think we want to think about this more broadly speaking in the sense that there may be some health span metrics that are particularly and potently positively impacted by people just also want to make sure there's no negative lifespan though that's the thing too.”
Main Takeaways:
- Lifespan may not be the most crucial metric for evaluating the efficacy of rapamycin in dogs or humans.
- Health span improvements are also significant metrics to consider.
- It's essential to ensure that treatments do not negatively impact lifespan.
Notes: Discussion on the importance of health span versus lifespan in clinical studies
Tone: Cautious
Relevance: 4/5
“I would be shocked if we see a shortening of lifespan from Rapa mice and treatment just given everything that I know to this point in mice and the data we've gotten so far in dogs.”
Main Takeaways:
- The speaker expects no reduction in lifespan from rapamycin treatment based on existing data from mice and dogs.
- Confidence is expressed based on prior studies and observations.
Notes: Expressing expectations based on previous research outcomes
Tone: Confident
Relevance: 4/5
“Rapa may be having positive survival effects in marma sets so again I think if that pans out and we actually see a statistically significant Improvement in lifespan from marac sets that's really important because now it's gotten to the point of a primate right which we don't have data for yet obviously closer to humans.”
Main Takeaways:
- Preliminary results suggest rapamycin may improve survival in marmosets.
- Significant because it extends findings to primates, which are closer to humans in biological terms.
Notes: Discussing ongoing research and its implications for primate studies
Tone: Optimistic
Relevance: 4/5
“A lot of these are n of one experiments with people who are changing their regimens as they go so there are some people who are taking you know six milligrams once a week but they're trying to build it up to some higher dose to see where they start to get side effects.”
Main Takeaways:
- Individuals are self-experimenting with varying doses of substances to observe effects.
- The goal is to determine personal tolerance and side effects.
Tone: Neutral
Relevance: 4/5
“There are a bunch of people who reported taking grapefruit juice with their rapamycin because grapefruit juice will inhibit cytochrome p450s and enhance bioavailability of rapamycin.”
Main Takeaways:
- Grapefruit juice is used to inhibit cytochrome p450 enzymes, enhancing the bioavailability of rapamycin.
- This practice is part of self-experimentation to potentially increase the effectiveness of the drug.
Tone: Neutral
Relevance: 4/5
“Rapamycin is unstable at gastric pH and so if compounded rapamycin is not in an enteric coated capsule you're essentially going to get zero bioavailability.”
Main Takeaways:
- Rapamycin's stability is compromised by gastric pH, requiring protective formulation.
- Enteric coated capsules are necessary to ensure rapamycin's bioavailability when ingested.
Tone: Cautious
Relevance: 5/5
“I don't know that that's been even carefully done has anybody looked at rapamycin Administration and antimullerian hormone level for example um you know once let's say a woman is already in her AMH decline but hasn't fully bottomed out to zero could you rescue some of that.”
Main Takeaways:
- Rapamycin administration may impact antimullerian hormone (AMH) levels, which are indicative of a woman's ovarian reserve.
- The potential for rapamycin to rescue declining AMH levels in women is being questioned.
- AMH levels typically decrease as women age, impacting fertility.
Notes: Discussion on the potential effects of rapamycin on hormone levels in women.
Tone: Inquisitive
Relevance: 4/5
“I still think we are really in early days of understanding what pharmacologic inhibition of mTOR can do.”
Main Takeaways:
- Pharmacologic inhibition of mTOR is under investigation for its potential benefits in aging.
- Research is still in early stages, and its effectiveness in humans is not yet confirmed.
Notes: Discussion on a recent podcast about aging research.
Tone: Cautious
Relevance: 4/5
“we have great evidence now for at least three mutants and the calor restriction diet and the methionine restriction diet and we're getting there for rapy and several of the other drugs that came along”
Main Takeaways:
- Evidence supports the effectiveness of certain mutants and diets like calor restriction and methionine restriction in anti-aging.
- Research is progressing on rapamycin and other drugs for their potential anti-aging effects.
Notes: Speaker discussing the evidence supporting various anti-aging interventions.
Tone: Optimistic
Relevance: 5/5
“the famous One the early one was rap ayin about 90% of the Romy that was given to mice in the food never made it into the mouse because it's digested in the stomach and the acid conditions of the stomach it gets degraded”
Main Takeaways:
- Rapamycin, when administered orally, is largely degraded in the stomach due to acidic conditions.
- Only about 10% of orally administered rapamycin reaches systemic circulation in mice.
- This degradation limits the drug's effectiveness when given in food.
Notes: Discussing challenges in drug delivery in mice studies.
Tone: Informative
Relevance: 5/5
“Randy with colleagues of his uh worked out a way to encapsulate the Romy in a capsule plastic capsule that makes it through the stomach and dissolves in the more alkaline conditions of the small intestine.”
Main Takeaways:
- Encapsulation technology was developed to protect rapamycin from stomach acid.
- The capsule ensures rapamycin is released in the small intestine where conditions are more favorable for absorption.
- This method improves the bioavailability of rapamycin in mice.
Notes: Solution to the problem of rapamycin degradation discussed earlier.
Tone: Solution-oriented
Relevance: 5/5
“what rap mice and appears to do in their model is increases the production of B cells from the bone marrow so the mice would respond to influenza vaccine and then they were exposed to live virus and they survive”
Main Takeaways:
- Rapamycin may boost immune function by increasing B cell production from the bone marrow.
- This increase in B cells enhances the response to influenza vaccines in mice.
- Mice treated with rapamycin survived exposure to live virus better than untreated controls.
Notes: Discussion on the immune-boosting effects of rapamycin in mice
Tone: Neutral
Relevance: 5/5
“five drugs it's actually four four drugs published one is actually another mutant”
Main Takeaways:
- Four drugs have been published as influencing aging rates.
- One additional substance initially thought to be a drug is actually another genetic mutant.
Notes: Clarification on the number and type of substances affecting aging
Tone: Neutral
Relevance: 4/5
“if you give a drug to a mouse how long does it take for the Aging rate indicators to switch”
Main Takeaways:
- Drugs can alter aging rate indicators in mice.
- The time it takes for these indicators to switch is a critical factor in aging research.
Notes: Exploring the immediate effects of drugs on aging indicators in animal models
Tone: Neutral
Relevance: 5/5
“but we have great evidence now for at least three mutants and the calor restriction diet and the methionine restriction diet and we're getting there for rapamycin and several of the other drugs that came along you know five years eight years after that so I think there will be a very strong case that these drugs are acting by slowing the aging process and delaying maybe not quite all but maybe all of the aspects of Aging that make people unhappy about getting older.”
Main Takeaways:
- Caloric restriction and methionine restriction diets have strong evidence supporting their role in slowing aging.
- Rapamycin and other drugs developed later are also believed to slow the aging process.
- These interventions may delay various aspects of aging that contribute to dissatisfaction in older age.
Notes: Discussion on the effectiveness of certain diets and drugs on aging.
Tone: Optimistic
Relevance: 5/5
“And so we're going to talk about NAD boosters. We're going to talk about Metformin, berberine, rapamycin, spermidine, resveratrol, fisetin and quercetin, and probably a few others.”
Main Takeaways:
- Discussion will cover a range of substances including NAD boosters, Metformin, and others.
- These substances are linked to health span and lifespan enhancement.
Tone: enthusiastic
Relevance: 5/5
“So that's how mTOR was discovered. And when you give animals rapamycin, you're mimicking low protein intake.”
Main Takeaways:
- Rapamycin inhibits mTOR, which is a pathway involved in protein sensing.
- Giving rapamycin to animals simulates conditions of low protein intake.
Notes: Discussion on mTOR and its discovery
Tone: Informative
Relevance: 4/5
“Rapatha steps in it's a monoconal antibbody it's just an antibbody that blocks PCSK9's it inhibits them it stops that protein from destroying the LDL receptors the more receptors the more LDL is cleared out of your bloodstream”
Main Takeaways:
- Rapatha is a monoclonal antibody that inhibits PCSK9, enhancing the function of LDL receptors.
- By blocking PCSK9, Rapatha increases the clearance of LDL from the bloodstream, potentially reducing cardiovascular risk.
Notes: Explanation of how Rapatha works as a treatment
Tone: Informative
Relevance: 5/5
“I was doing rapamycin for a while and I just recently stopped after doing it for four years.”
Main Takeaways:
- The speaker was using rapamycin for four years.
- They recently stopped using it.
Notes: Part of a discussion on using substances to enhance abilities.
Tone: Neutral
Relevance: 4/5
“It was messing with my lipids, blood glucose, resting heart rate was increased and I had some small tissue infections.”
Main Takeaways:
- Rapamycin affected the speaker's lipids and blood glucose levels.
- It increased their resting heart rate and caused small tissue infections.
Notes: Reasons for discontinuing rapamycin.
Tone: Concerned
Relevance: 5/5
“Rapamycin showed it accelerated the speed of aging epigenetically.”
Main Takeaways:
- Recent research suggests rapamycin may accelerate aging epigenetically.
- This was based on a preprint observing effects on aging clocks.
Notes: Discussing recent findings on rapamycin.
Tone: Informative
Relevance: 4/5
“a lot of the press is oriented around this, the sexiness of things like rapamycin and Metformin and sirtuins and the like, which is very different than the kind of longevity science that you're interested in and focused on.”
Main Takeaways:
- Rapamycin, Metformin, and sirtuins are often highlighted in media discussions about longevity.
- These substances are associated with the more glamorous side of longevity research.
- The speaker contrasts these substances with other aspects of longevity science that may be less publicized but are of interest.
Notes: Discussion on different aspects of longevity science
Tone: Neutral
Relevance: 4/5
“So we were probably the first lab in the world that was working out rapamycin and longevity. And my lab discovered the role of the TOR pathway in aging in 2001.”
Main Takeaways:
- The speaker's lab was among the first to research the effects of rapamycin on longevity.
- They discovered the role of the TOR pathway in aging.
Notes: Speaker discussing their research history
Tone: Proud
Relevance: 5/5
“And guess what, if you block TOR in people with rapamycin, they become hypoglycemic and mice become hypoglycemic.”
Main Takeaways:
- Blocking the TOR pathway with rapamycin can lead to hypoglycemia in both humans and mice.
- This highlights a potential side effect of using rapamycin for longevity.
Notes: Discussing potential side effects of rapamycin
Tone: Cautious
Relevance: 5/5
“there is M total long-term metformin study and then a lot of people are actually consuming good amount of rapamycin off level they can get their own”
Main Takeaways:
- Metformin and rapamycin are being used by individuals interested in their potential longevity benefits.
- There is ongoing interest in the long-term effects of these substances on human health.
Tone: Curious
Relevance: 4/5
“I don't take rapamycin, I don't take Metformin, I don't even take berberine which is poorman's metformin it um makes me very hypoglycemic for reasons that make total sense based on the mechanisms of metformin and berberine”
Main Takeaways:
- The speaker avoids certain substances like rapamycin, Metformin, and berberine due to personal adverse effects such as hypoglycemia.
- These substances are known for their potential longevity benefits but also come with side effects.
Notes: Personal anecdote regarding the avoidance of certain longevity substances.
Tone: Cautious
Relevance: 4/5
“fasting is one of the dirtiest drugs you could ever imagine it probably changes a million different chemical reactions and proteins and metabolites so fasting is going to do a lot more than rapamy does.”
Main Takeaways:
- Fasting affects a wide range of biochemical processes.
- It impacts numerous chemical reactions, proteins, and metabolites.
- Fasting has broader biological effects compared to specific drugs like rapamycin.
Notes: Comparing the biochemical impact of fasting to rapamycin.
Tone: Neutral
Relevance: 5/5
“I think two darlings of the anti-aging industry as far as off label drugs are metformin and rapamycin.”
Main Takeaways:
- Metformin and rapamycin are popular in the anti-aging industry.
- These drugs are used off-label for their potential anti-aging effects.
Tone: Neutral
Relevance: 4/5
“rapamycin can be unsuccessful as a chemotherapeutic agent and can yet be very successful as a cancer preventive agent”
Main Takeaways:
- Rapamycin may not always be effective as a treatment for existing cancers.
- Rapamycin has potential as a preventive measure against cancer.
- The effectiveness of rapamycin in cancer prevention highlights its role in biological aging.
Notes: Discussion on the dual role of rapamycin in cancer treatment and prevention
Tone: Informative
Relevance: 5/5
“because inhibiting mtor increases lifespan and slows aging”
Main Takeaways:
- Inhibition of the mTOR pathway is associated with increased lifespan and slowed aging in experimental models.
- mTOR inhibitors like rapamycin are being studied for their potential longevity benefits.
Notes: Discussion on the effects of mTOR inhibition on aging
Tone: Informative
Relevance: 5/5
“Linda Partridge just published in bioarchive at least a nice paper Rapa mice and increased lifespan for mice if she added an inhibitor of a different kise called irk it did better it did the inhibition by irk work by itself but it actually improved on rapy.”
Main Takeaways:
- Research by Linda Partridge showed that combining an inhibitor called irk with rapamycin increased lifespan in mice.
- The inhibitor worked on its own but had enhanced effects when combined with rapamycin.
Notes: Discussing recent research findings
Tone: Informative
Relevance: 5/5
“most people using ramyon off label for potential Health span effects most doctors prescribing it are recommending once weekly dosing you know in the 3 to six sometimes 8 10 milligram range.”
Main Takeaways:
- Rapamycin is commonly used off-label to potentially extend healthspan, with most prescriptions recommending once-weekly dosing.
- Dosing ranges typically from 3 to 10 milligrams per week.
Notes: Discussing common off-label use and dosing of rapamycin
Tone: Informative
Relevance: 5/5
“i probably get an equal number of questions near about the following three things: metformin, rapamycin, or some combination of nr nad or nmn”
Main Takeaways:
- Metformin, rapamycin, and NAD/NMN supplements are common topics of interest in discussions about aging and longevity.
- These supplements are associated with geroprotection, attracting attention for their potential anti-aging benefits.
Notes: Speaker discusses the frequency of questions they receive about certain supplements.
Tone: Informative
Relevance: 4/5
“I take a few right so I take some that are disease specific right so I take a pcsk9 inhibitor I take bidic acid uh I take an sglt2 inhibitor um and then I take at least one that is purely just uh based on the belief of its capacity and Juro protection which is rrap ayin and um and also the SG the sglt2 inhibitor I think is probably just broadly geroprotective.”
Main Takeaways:
- The speaker takes several supplements, some for disease-specific reasons and others for general health protection.
- Mentions taking a PCSK9 inhibitor, bidic acid, and an SGLT2 inhibitor.
- Rapamycin is taken based on its believed capacity for neuroprotection and general geroprotection.
Notes: Discussing personal supplement regimen
Tone: Informative
Relevance: 5/5
“what dosage of rapamycin do you take I take eight milligrams once a week for as long as I can tolerate it but that I usually have to take breaks.”
Main Takeaways:
- The speaker takes 8 mg of rapamycin once a week.
- Mentions needing to take breaks from rapamycin due to side effects.
Notes: Discussing personal dosage and tolerance
Tone: Cautious
Relevance: 5/5
“I get these vicious apus ulcers uh little mouth sores canker Source yes about 10% of people get them.”
Main Takeaways:
- The speaker experiences side effects from rapamycin, specifically mouth ulcers.
- Mentions that about 10% of people taking rapamycin experience similar side effects.
Notes: Discussing side effects of rapamycin
Tone: Cautious
Relevance: 4/5
“my conviction around mtor is far more based on the experimental data um something that is actually sorely lacking in the NAD story which we'll discuss so the experimental data are far more convincing right which is when you look at the administration of Ramy or its analoges for example ever alus um when you look at the administration of these molecules to organisms that are as close as possible to the species of interest.”
Main Takeaways:
- The speaker's belief in the effectiveness of mTOR inhibitors like rapamycin is based on experimental data.
- Highlights the lack of convincing data for NAD compared to mTOR inhibitors.
- Discusses the administration of rapamycin and its analogs to various organisms close to humans in biological terms.
Notes: Comparing experimental data of mTOR inhibitors and NAD
Tone: Confident
Relevance: 4/5
“One of the things that I hope gets a lot more attention is the use of rapamycin for preserving ovarian health.”
Main Takeaways:
- Rapamycin has shown potential in animal studies to preserve ovarian health.
- Clinical trials in women are anticipated to further explore this potential.
Notes: Discussion on potential treatments for ovarian health
Tone: Hopeful
Relevance: 4/5
“I'm a huge proponent of rapamycin.”
Main Takeaways:
- Peter supports the use of rapamycin.
- Rapamycin is discussed in the context of longevity without direct human trials proving life extension.
Notes: Discussion on the use of rapamycin for GRo protective effects without human clinical trials.
Tone: Supportive
Relevance: 4/5
No comments yet.